U.S. Pharma Stock News

Maximus (MMS) has quietly delivered a steady climb this year, with shares up about 16% year to date and 23% over the past year. This performance reflects improving fundamentals and consistent execution. See our latest analysis for Maximus. With the share price now around $88.26 and a solid year to date share price return, recent gains look more like a steady re-rating of Maximus as investors warm to its growth and earnings trajectory rather than a short lived bounce. This reinforces a...

If you are wondering whether Trane Technologies is still worth buying at today’s price, you are not alone. This article will walk through what the current share price actually implies about its value. After a huge multiyear run, the stock has cooled slightly, with the share price down around 1.3% over the last week and 4.9% over the past month, but still up 4.3% year to date and 137.6% over three years. That kind of performance has been supported by growing enthusiasm for energy efficient...

If you have been wondering whether Cisco Systems is still a buy after its big run, you are not alone. This article is all about what the current price really says about its value. Despite a minor 0.2% pullback over the last week, the stock is up 2.6% over 30 days and 32.2% year to date, adding to a 35.9% gain over 1 year and more than doubling over 5 years. Those gains have come as investors refocus on Cisco's role in network infrastructure and security, especially as enterprises modernize...

Brown & Brown (BRO) has quietly drifted lower this year, leaving the stock down about 21% over the past year, even as revenue and net income keep growing at roughly 15% annually. See our latest analysis for Brown & Brown. With the share price now around $80.37 and the 90 day share price return of negative 12.82 percent, sentiment looks like it is cooling even though the five year total shareholder return of 81.17 percent still points to a solid long term compounding story. If Brown & Brown...

Americold Realty Trust, Inc. recently declared a fourth-quarter 2025 cash dividend of US$0.23 per share, payable on January 15, 2026 to stockholders of record as of December 31, 2025, matching the third quarter payout and representing a 5% increase from the prior year. The company also added Joseph Reece and Stephen Sleigh to its Board and formed a new Finance Committee under a cooperation agreement with Ancora Group Holdings, signaling an intensified focus on capital allocation, governance...

QUALCOMM (QCOM) has quietly outpaced the broader market over the past month, and that recent strength is catching investors attention as they reassess the chipmaker s long term earnings and growth trajectory. See our latest analysis for QUALCOMM. That strength comes after a solid stretch where QUALCOMM has delivered a 13.39 percent year to date share price return and a hefty 68.25 percent three year total shareholder return, suggesting momentum is gradually rebuilding around its growth...

Quanta Services recently reported that its project backlog has grown at an average rate of 16.7% over the past two years, while earnings per share compounded at 24.3% annually, highlighting a solid pipeline of contracted work and strong profitability trends. This combination of sustained backlog expansion and faster earnings growth than peers points to a company that is increasingly converting demand into higher-quality, higher-margin business. Next, we'll examine how Quanta's rapid...

Charles River Laboratories International (CRL) just got a double dose of good news, with the U.S. SEC closing its investigation without enforcement action and BofA Securities upgrading the stock, helping shares climb about 3%. See our latest analysis for Charles River Laboratories International. That relief rally builds on strong recent momentum, with a 30 day share price return of about 21 percent and a 90 day gain above 35 percent, even though the five year total shareholder return remains...

If you are wondering whether Howmet Aerospace is still worth considering after such a large run up, or if you are late to the party, this breakdown will walk through what the current price might really be telling you. The stock has climbed 5.5% over the last week and month, and is now up an eye catching 87.9% year to date and 88.8% over the past year, with a massive 661.0% gain over five years reshaping how investors perceive its potential and risk. Recent headlines have focused on Howmet's...

KULR Technology Group has paused its at-the-market equity offering program through June 30, 2026, while advancing its KULR ONE Air and next-generation KULR ONE MAX battery backup solutions targeting AI data centers and telecommunications. Recent collaborations around ORV3-compliant, 21700 cell-based Battery Backup Units and KULR’s Platinum membership in the Open Compute Project highlight a pivot toward mission-critical AI data center energy infrastructure built around its safety-focused KULR...

Tradeweb Markets (TW) has quietly outperformed over the past week, even as its stock is still down almost 20% this year. This sets up an interesting backdrop for anyone reassessing the long term story. See our latest analysis for Tradeweb Markets. That recent uptick in the share price sits in stark contrast to Tradeweb Markets' roughly 19% year to date share price decline. At the same time, the three and five year total shareholder returns still point to a solid long term compounding story,...

PVH (PVH) has quietly slid over the past month, giving back close to 9%, and is down about 21% in the past 3 months, even as its underlying business continues to grow. See our latest analysis for PVH. Zooming out, PVH’s share price return has been weak this year, with the 1 year total shareholder return also negative. This suggests momentum has clearly faded despite steady revenue and profit growth. If PVH’s recent slide has you rethinking where to put fresh capital, it could be a good moment...

Incyte (INCY) just caught investors attention after Japan granted back to back approvals for its cancer drugs Minjuvi and Zynyz, expanding the company international footprint and strengthening its non United States revenue story. See our latest analysis for Incyte. Those back to back approvals arrive while Incyte's share price has climbed to about $100.71, with a strong year to date share price return supported by a robust one year total shareholder return, suggesting momentum is building as...

Why Pennant Group Is Back on Investors Radar Pennant Group (PNTG) has quietly outpaced much of the market over the past few months, with the stock climbing about 10% over the past month and 20% in the past 3 months. See our latest analysis for Pennant Group. That recent 30 day share price return of 10.42 percent and 90 day gain of 20.20 percent, alongside a 3 year total shareholder return nearing 196 percent, suggest momentum is rebuilding as investors reassess Pennant Group growth profile...

Earlier in December, Philip Morris International’s board declared a regular quarterly dividend of US$1.47 per share, payable on January 14, 2026, to shareholders of record and ex-dividend as of December 26, 2025. On the financing side, PMI lined up a new US$2.00 billion revolving credit facility and extended a separate €1.50 billion line, reinforcing its liquidity while it leans into higher-margin smoke-free products after a stronger-than-expected quarter. We’ll now examine how PMI’s new...

In December 2025, Truist Financial announced a new electronic direct deposit switching feature embedded in its digital onboarding, expanded AI-enabled tools such as Truist Assist and Truist Insights, and introduced a new wealth platform while its Board authorized a US$10.00 billion share repurchase program with no expiration date. Together, these moves highlight Truist’s push to blend technology-enabled convenience with capital returns, aiming to deepen client relationships while actively...

Dillard’s recently announced the upcoming closure of its Plano, Texas store in early 2026 with related layoffs, amid broader market volatility and questions around its valuation and insider share sales. This comes after a year in which the retailer paired steady operations with aggressive shareholder returns, including a US$30.00 special dividend, highlighting a tension between cash returns and investor caution. We’ll now examine how the planned Plano store closure and associated workforce...

TXNM Energy (TXNM) has quietly delivered a solid run, gaining about 26% over the past year as investors warm to its regulated footprint in New Mexico and Texas and its improving earnings profile. See our latest analysis for TXNM Energy. The steady 20.66% year to date share price return, capped by a recent close at $58.93, alongside a 25.96% one year total shareholder return, suggests momentum is quietly building as investors reassess its regulated growth story and earnings resilience. If...

Jackson Financial (JXN) has quietly put up solid numbers, with annual revenue and net income both growing around 9% and 14%. That kind of steady progress is starting to draw more valuation-focused attention. See our latest analysis for Jackson Financial. The stock has backed that earnings momentum with a strong 30 day share price return of 14.66 percent and an impressive three year total shareholder return of 252.93 percent, suggesting momentum is still firmly on Jackson Financial's side. If...

In recent months, DexCom has seen mixed reactions from Wall Street as Morgan Stanley upgraded the stock, Evercore ISI initiated coverage with a more cautious stance, the FDA cleared its Dexcom Smart Basal insulin dosing optimizer for adults with Type 2 diabetes, and multiple securities class action lawsuits were filed over alleged misstatements about G6 and G7 device reliability and manufacturing. This combination of regulatory progress, differing analyst views, and legal scrutiny...

Earlier this month, Polestar Automotive Holding UK PLC raised US$300.0 million by selling 15,511,892 Class A ADSs via a PIPE at US$19.34 each, while also securing access to a US$600.0 million term loan facility from Geely Sweden Automotive Investment AB for general corporate purposes. The combination of fresh equity and a sizable short-term loan with an option for share conversion materially strengthens Polestar’s funding runway but also introduces dilution and capital structure...

In December 2025, Pacira BioSciences announced it had joined the European Innovative Health Initiative-funded PROBE Consortium, a global public-private effort using AI and a regulation-compliant big-data network spanning more than 70 million osteoarthritis patient records to improve OA diagnosis, treatment evaluation, and shared decision-making. This move directly aligns Pacira’s non-opioid analgesics, OA-focused products, and PCRX-201 gene therapy program with a large-scale infrastructure...

Science Applications International Corporation recently appointed Ravi Dankanikote as Chief Growth Officer, reporting to interim CEO Jim Reagan and tasked with leading the company’s enterprise growth strategy and go-to-market approach. This leadership change comes shortly after SAIC delivered a strong quarter with earnings surpassing analyst expectations and full-year EPS guidance raised more than peers, underscoring management’s focus on profitability and growth execution. We’ll now examine...

In recent weeks, analysts reiterated positive views on Viking Therapeutics after competitor Eli Lilly reported supportive Phase 3 results for a similar oral obesity therapy, reinforcing confidence in Viking’s lead candidate VK2735 and its broader metabolic pipeline. This combination of bullish analyst coverage and external clinical validation highlights how Viking, still without approved products, is increasingly viewed as a potential participant in large obesity and NASH markets. We’ll now...